Open access
Open access
Powered by Google Translator Translator

Oncology - Lung

Perspective | New lung cancer screening guideline comes with many caveats

14 Mar, 2021 | 20:23h | UTC

New lung cancer screening guideline comes with many caveats – Lown Institute

Original Guideline: USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk (article and commentaries)

 


USPSTF Statement: begin screening for lung cancer at age 50 years instead of 55 years for patients at risk

10 Mar, 2021 | 08:28h | UTC

Recommendation Statement: Screening for Lung Cancer – US Preventive Services Task Force

Editorials: Broadened Eligibility for Lung Cancer Screening: Challenges and Uncertainty for Implementation and Equity – JAMA AND Expanded Access to Lung Cancer Screening—Implementing Wisely to Optimize Health – JAMA Network Open AND New USPSTF Guidelines for Lung Cancer Screening: Better but Not Enough – JAMA Surgery AND The 2021 US Preventive Services Task Force Recommendation on Lung Cancer Screening: The More Things Stay the Same… – JAMA Oncology

 


Five-year outcomes from randomized, phase III trials: Nivolumab vs. Docetaxel in previously treated non–small-cell lung cancer

3 Mar, 2021 | 08:10h | UTC

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer – Journal of Clinical Oncology

 

Commentary on Twitter

 


ASCO Guideline: Management of dyspnea in advanced cancer

24 Feb, 2021 | 02:10h | UTC

Management of Dyspnea in Advanced Cancer: ASCO Guideline – Journal of Clinical Oncology

 

Commentary on Twitter (thread – click for more)

 


Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

19 Feb, 2021 | 02:04h | UTC

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update – Journal of Clinical Oncology

 


RCT: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%

18 Feb, 2021 | 02:34h | UTC

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial – The Lancet

 

Commentary on Twitter

 


Radiation therapy for small-cell lung cancer: ASCO Guideline endorsement of an ASTRO Guideline

29 Jan, 2021 | 01:27h | UTC

Radiation Therapy for Small-Cell Lung Cancer: ASCO Guideline Endorsement of an ASTRO Guideline – Journal of Clinical Oncology

 


Stay Updated in Your Specialty

No spam, just news.